NCT06251648View on ClinicalTrials.gov

Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)

Not yet recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 15, 2024

Study Completion Date

March 31, 2024

Conditions
Cancer
Interventions
DRUG

Lenalidomide

Patients exposed to LEN

Trial Locations (1)

14033

CHU de Caen, Caen

All Listed Sponsors
lead

University Hospital, Caen

OTHER

NCT06251648 - Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL) | Biotech Hunter | Biotech Hunter